Dominant optic atrophy: Culprit mitochondria in the optic nerve

Area of Science:

• Ophthalmology and Genetics
• Mitochondrial Biology
• Neuroscience

Background:

• Dominant optic atrophy (DOA) is an inherited mitochondrial disease affecting retinal ganglion cells (RGCs), causing vision loss.
• Heterozygous mutations in the OPA1 gene are the most frequent cause of DOA, impacting mitochondrial function.
• DOA can present as a syndromic disorder with additional neurological and muscular symptoms.

Purpose of the Study:

• To review and synthesize current data on DOA pathophysiology, focusing on OPA1 functions and RGC peculiarities.
• To explore novel pathophysiological mechanisms and biomarkers associated with OPA1 mutations.
• To propose potential therapeutic approaches for DOA.

Main Methods:

• Review of existing literature on Dominant Optic Atrophy (DOA) and OPA1 gene.
• Analysis of data from three DOA mouse models with different Opa1 mutations.
• Metabolomics analyses of cells, mouse organs, and patient plasma.

Main Results:

• OPA1 protein is crucial for mitochondrial structure, fusion, and function, including oxidative phosphorylation and apoptosis regulation.
• DOA mouse models exhibit RGC degeneration and secondary mitochondrial dysfunction, mirroring human syndromic phenotypes.
• Metabolomics studies identified novel pathophysiological mechanisms and disease severity biomarkers in OPA1-mutated subjects.

Conclusions:

• Understanding OPA1's role in RGCs is key to deciphering DOA pathophysiology.
• New insights into mitochondrial dysfunction and biomarkers offer avenues for therapeutic development.
• Further research and therapeutic strategies are needed to address the unmet clinical needs of DOA patients.